AR055314A1 - Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo - Google Patents

Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo

Info

Publication number
AR055314A1
AR055314A1 ARP060100679A ARP060100679A AR055314A1 AR 055314 A1 AR055314 A1 AR 055314A1 AR P060100679 A ARP060100679 A AR P060100679A AR P060100679 A ARP060100679 A AR P060100679A AR 055314 A1 AR055314 A1 AR 055314A1
Authority
AR
Argentina
Prior art keywords
hemicetal
understands
prepare
procedure
pharmaceutical composition
Prior art date
Application number
ARP060100679A
Other languages
English (en)
Inventor
Hyun-Ik Shin
Hyeong-Wook Choi
Tae-Ho Heo
Jae Hoon Lee
Ki-Sook Park
Kyu Woong Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR055314A1 publication Critical patent/AR055314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Procesos de obtencion de dichos compuestos y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula (1), caracterizado porque: R1 es alquilo o arilo; y R2 es alquilo.
ARP060100679A 2005-02-26 2006-02-24 Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo AR055314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050016203 2005-02-26

Publications (1)

Publication Number Publication Date
AR055314A1 true AR055314A1 (es) 2007-08-15

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100679A AR055314A1 (es) 2005-02-26 2006-02-24 Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo

Country Status (29)

Country Link
US (1) US8044080B2 (es)
EP (1) EP1851214B1 (es)
JP (1) JP4961357B2 (es)
KR (1) KR100774999B1 (es)
CN (1) CN101128459B (es)
AP (1) AP2374A (es)
AR (1) AR055314A1 (es)
AU (1) AU2006217293B2 (es)
BR (1) BRPI0607330B1 (es)
CA (1) CA2598347C (es)
DK (1) DK1851214T3 (es)
EA (1) EA013005B1 (es)
ES (1) ES2394480T3 (es)
HK (1) HK1111146A1 (es)
IL (1) IL185226A0 (es)
MA (1) MA29311B1 (es)
MX (1) MX2007010338A (es)
MY (1) MY149181A (es)
NO (1) NO341347B1 (es)
NZ (1) NZ560805A (es)
PE (1) PE20061076A1 (es)
PL (1) PL1851214T3 (es)
PT (1) PT1851214E (es)
SG (1) SG156689A1 (es)
SI (1) SI1851214T1 (es)
TW (1) TWI377205B (es)
UA (1) UA94395C2 (es)
WO (1) WO2006090997A1 (es)
ZA (1) ZA200707202B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
AR072181A1 (es) * 2008-07-11 2010-08-11 Gilead Sciences Inc Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP6118907B2 (ja) * 2012-09-28 2017-04-19 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 植物病害を防除するための窒素含有ヘテロ環式化合物
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
WO2018133870A1 (zh) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
KR102437095B1 (ko) * 2019-04-19 2022-08-26 주식회사 엘지화학 캐스파제 저해제의 프로드럭
CN113767097A (zh) * 2019-04-30 2021-12-07 株式会社Lg化学 半胱天冬酶抑制剂的前药
EP3970698A4 (en) * 2019-05-31 2022-08-31 LG Chem, Ltd. INJECTABLE COMPOSITION WITH PRODRUG OF CASPASE INHIBITORS AND METHOD OF MANUFACTURE THEREOF
US20220226306A1 (en) * 2019-05-31 2022-07-21 Lg Chem, Ltd. Composition for caspase inhibitor prodrug injection
JP2023537012A (ja) * 2020-08-05 2023-08-30 エルジー・ケム・リミテッド 変形性関節症の緩和又は治療するためのカスパーゼ阻害剤の使用
KR20220076371A (ko) 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
WO2023132606A1 (ko) * 2022-01-04 2023-07-13 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
WO2023140582A1 (ko) * 2022-01-24 2023-07-27 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제
KR20230126654A (ko) 2022-02-23 2023-08-30 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법
WO2023182877A1 (ko) 2022-03-24 2023-09-28 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
KR19990079267A (ko) 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
AU5762899A (en) 1999-09-17 2001-04-24 Lg Chemical Ltd. Caspase inhibitor
CA2388564C (en) * 1999-09-17 2007-11-06 Lg Chem Investment Ltd. Caspase inhibitor
TWI256952B (en) * 2003-08-27 2006-06-21 Sk Corp Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders
KR100594544B1 (ko) * 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제

Also Published As

Publication number Publication date
EA200701810A1 (ru) 2008-02-28
IL185226A0 (en) 2008-02-09
AP2374A (en) 2012-03-07
EP1851214B1 (en) 2012-09-05
BRPI0607330B1 (pt) 2021-08-03
UA94395C2 (ru) 2011-05-10
US8044080B2 (en) 2011-10-25
HK1111146A1 (en) 2008-08-01
MA29311B1 (fr) 2008-03-03
WO2006090997A1 (en) 2006-08-31
EP1851214A4 (en) 2009-10-28
MX2007010338A (es) 2007-10-11
ZA200707202B (en) 2008-10-29
CN101128459B (zh) 2011-10-05
TWI377205B (en) 2012-11-21
PL1851214T3 (pl) 2013-03-29
NO341347B1 (no) 2017-10-16
EP1851214A1 (en) 2007-11-07
US20080262032A1 (en) 2008-10-23
JP4961357B2 (ja) 2012-06-27
JP2008531551A (ja) 2008-08-14
NO20074895L (no) 2007-11-26
KR100774999B1 (ko) 2007-11-09
KR20060094868A (ko) 2006-08-30
CN101128459A (zh) 2008-02-20
TW200640918A (en) 2006-12-01
CA2598347C (en) 2011-08-02
SG156689A1 (en) 2009-11-26
MY149181A (en) 2013-07-31
SI1851214T1 (sl) 2012-11-30
ES2394480T3 (es) 2013-02-01
AU2006217293A1 (en) 2006-08-31
CA2598347A1 (en) 2006-08-31
NZ560805A (en) 2010-12-24
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
PE20061076A1 (es) 2006-12-27
BRPI0607330A2 (pt) 2009-09-29
PT1851214E (pt) 2012-10-18
EA013005B1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
AR055314A1 (es) Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP099600A (es) Co-cristales y composicón farmaceútica de los mismos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CO6501153A2 (es) Inhibidores macrociclicos de serina proteasa
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP10010271A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
HN2009000792A (es) Inhibidores de la proteasa ns3 del hcv
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
UY30610A1 (es) Moduladores de mglur5
CO2019002692A2 (es) Nuevos derivados de isoxazolil éter como pam de gaba a alfa5.
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)

Legal Events

Date Code Title Description
FG Grant, registration